Abstract
Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.
Keywords: Animal model, chemoprevention, clinical trial, hepatocellular carcinoma, liver cirrhosis, prevention, bile duct ligation, carbon tetrachloride, connective tissue growth factor, direct acting antiviral, diethylnitrosamine, dimethylnitrosamine, extracellular matrix, epidermal growth factor, genetic hemochromatosis
Current Cancer Drug Targets
Title:Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges
Volume: 12 Issue: 9
Author(s): Yujin Hoshida, Bryan C. Fuchs and Kenneth K. Tanabe
Affiliation:
Keywords: Animal model, chemoprevention, clinical trial, hepatocellular carcinoma, liver cirrhosis, prevention, bile duct ligation, carbon tetrachloride, connective tissue growth factor, direct acting antiviral, diethylnitrosamine, dimethylnitrosamine, extracellular matrix, epidermal growth factor, genetic hemochromatosis
Abstract: Chronic fibrotic liver diseases such as viral hepatitis eventually develop liver cirrhosis, which causes occurrence of hepatocellular carcinoma (HCC). Given the limited therapeutic efficacy in advanced HCC, prevention of HCC development could be an effective strategy for improving patient prognosis. However, there is still no established therapy to meet the goal. Studies have elucidated a wide variety of molecular mechanisms and signaling pathways involved in HCC development. Genetically-engineered or chemically-treated experimental models of cirrhosis and HCC have been developed and shown their potential value in investigating molecular therapeutic targets and diagnostic biomarkers for HCC prevention. In this review, we overview potential targets of prevention and currently available experimental models, and discuss strategies to translate the findings into clinical practice.
Export Options
About this article
Cite this article as:
Hoshida Yujin, C. Fuchs Bryan and K. Tanabe Kenneth, Prevention of Hepatocellular Carcinoma: Potential Targets, Experimental Models, and Clinical Challenges, Current Cancer Drug Targets 2012; 12 (9) . https://dx.doi.org/10.2174/15680096112091129
DOI https://dx.doi.org/10.2174/15680096112091129 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Calculation of Molecular Features with Apparent Impact on Both Activity of Mutagens and Activity of Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Patent Selections
Recent Patents on Drug Delivery & Formulation An Overview of Labeled Porphyrin Molecules in Medical Imaging
Recent Patents and Topics on Imaging (Discontinued) Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Synthesis, Characterization and Antitumor Activity of Novel Triazole/ Isoxazole Tagged Pyridine Hybrids
Letters in Organic Chemistry Genomic and Pharmacogenomic Biomarkers of Parkinson’s Disease
Current Drug Metabolism Editorial [Hot Topic: Current Strategies in Vascular Biology (Guest Editor: Elisabeth Deindl)]
Current Pharmaceutical Biotechnology Control of Melanoma Invasiveness by Anticollagenolytic Agents: A Reappraisal of an Old Concept
Anti-Cancer Agents in Medicinal Chemistry Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Overview of the Role of Macrophage Migration Inhibitory Factor (MIF) in Inflammatory Bowel Disease
Current Pharmaceutical Design HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Form and Function in Cyclic Peptide Natural Products: A Pharmacokinetic Perspective
Current Topics in Medicinal Chemistry A Single Fas Gene Mutation Changes Lupus Onset, Severity, Location, and Molecular Abnormalities in Mice
Current Molecular Medicine Azoles as Effective Antifungal Agents: Trends, Scope and Relevance
The Natural Products Journal Isolation and Boactivities of Furfuran Type Lignan Compounds from Edible Plants
Recent Patents on Food, Nutrition & Agriculture Thermodynamics and Electro-Biologic Prospects for Therapies to Intervene in Cancer Progression
Current Cancer Therapy Reviews Can Targeted Therapy be Successful without Metronomic Scheduling ?
Current Topics in Medicinal Chemistry <i>Propionibacterium acnes</i> in the Pathogenesis and Immunotherapy of Acne Vulgaris
Current Drug Metabolism Synthesis, Antiproliferative Activity and Molecular Docking of New Thiazole/Benzothiazole Fused Pyranopyrimidine Derivatives
Letters in Organic Chemistry